SkinHealth Systems Inc. (SKIN)
Official siteCONSUMER DEFENSIVE • HOUSEHOLD & PERSONAL PRODUCTS • NASDAQ
Market Cap: $106.26M
Last updated: Nov 17, 2026 at 11:01 AM ET
SkinHealth Systems Inc. (SKIN) Earnings: Report Dates and Results
SkinHealth Systems (SKIN) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, SkinHealth Systems reported EPS of -$0.14, above the -$1.32 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SKIN has an expected report date of Mar 10, 2027.
SKIN Earnings Call
The latest SKIN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 24 quarters below that had an estimate, SKIN beat 17, missed 6 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $69.17M, down 2.1% from $70.66M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.14 | -$1.32 | N/A | +89.39% | Beat | -566.7% | 1 | 0 up, 0 down | Nov 5, 2026 | $69.17M |
| Jun 30, 2026 | -$0.02 | -$0.04 | -$0.06 - -$0.01 | +50.00% | Beat | -166.7% | 7 | 4 up, 0 down | Aug 6, 2026 | $72.11M |
| Mar 31, 2026 | $0.03 | -$0.01 | N/A | +400.00% | Beat | -25.0% | 7 | 1 up, 4 down | May 7, 2026 | $64.91M |
| Dec 31, 2025 | -$0.06 | -$0.04 | -$0.08 - -$0.02 | -58.73% | Miss | N/A | 6 | 1 up, 1 down | Mar 12, 2026 | $82.37M |
| Sep 30, 2025 | $0.03 | -$0.05 | -$0.06 - -$0.04 | +160.00% | Beat | -25.0% | 2 | 0 up, 0 down | Nov 6, 2025 | $70.66M |
| Jun 30, 2025 | $0.03 | -$0.06 | N/A | +150.00% | Beat | -62.5% | 1 | 0 up, 0 down | Aug 7, 2025 | $78.19M |
| Mar 31, 2025 | $0.04 | -$0.07 | -$0.07 - -$0.07 | +157.14% | Beat | -20.0% | 1 | 0 up, 0 down | May 8, 2025 | $69.58M |
| Dec 31, 2024 | -$0.08 | -$0.10 | -$0.13 - -$0.05 | +20.00% | Beat | -900.0% | 2 | 0 up, 0 down | Mar 12, 2025 | $83.50M |
| Sep 30, 2024 | $0.04 | -$0.04 | N/A | +200.00% | Beat | -20.0% | 6 | 0 up, 0 down | Nov 12, 2024 | $78.80M |
| Jun 30, 2024 | $0.08 | $0.01 | -$0.11 - $0.02 | +700.00% | Beat | -46.7% | 9 | 2 up, 0 down | Aug 8, 2024 | $90.59M |
| Mar 31, 2024 | $0.05 | -$0.07 | N/A | +171.43% | Beat | N/A | 9 | 0 up, 0 down | May 9, 2024 | $81.40M |
| Dec 31, 2023 | $0.01 | -$0.07 | -$0.12 - $0.00 | +114.29% | Beat | -80.0% | 8 | 0 up, 0 down | Mar 12, 2024 | $96.82M |
| Sep 30, 2023 | $0.05 | $0.09 | $0.07 - $0.11 | -44.44% | Miss | 0.0% | 8 | 1 up, 0 down | Nov 13, 2023 | $97.41M |
| Jun 30, 2023 | $0.15 | $0.05 | $0.03 - $0.11 | +200.00% | Beat | +1400.0% | 8 | 0 up, 0 down | Aug 9, 2023 | $117.48M |
| Mar 31, 2023 | -$0.04 | -$0.02 | -$0.07 - $0.02 | -100.00% | Miss | N/A | 9 | 0 up, 1 down | May 10, 2023 | $86.28M |
| Dec 31, 2022 | $0.05 | $0.04 | $0.00 - $0.07 | +25.00% | Beat | +400.0% | 8 | 0 up, 0 down | Feb 28, 2023 | $98.13M |
| Sep 30, 2022 | $0.05 | $0.02 | -$0.03 - $0.05 | +150.00% | Beat | +150.0% | 9 | 0 up, 0 down | Nov 8, 2022 | $88.79M |
| Jun 30, 2022 | $0.01 | $0.02 | N/A | -50.00% | Miss | -88.9% | N/A | 0 up, 1 down | Aug 9, 2022 | $103.54M |
| Mar 31, 2022 | -$0.06 | $0.01 | -$0.03 - $0.01 | -700.00% | Miss | N/A | 9 | 0 up, 0 down | May 10, 2022 | $75.42M |
| Dec 31, 2021 | $0.01 | -$0.02 | -$0.04 - $0.00 | +150.00% | Beat | N/A | 8 | N/A | Feb 22, 2022 | $77.89M |
| Sep 30, 2021 | $0.02 | -$0.01 | -$0.03 - $0.01 | +300.00% | Beat | N/A | 6 | 2 up, 1 down | Nov 9, 2021 | $68.15M |
| Jun 30, 2021 | $0.09 | $0.02 | -$0.02 - $0.02 | +350.00% | Beat | N/A | 6 | N/A | Jul 1, 2021 | $66.51M |
| Mar 31, 2021 | -$0.06 | -$0.02 | N/A | -200.00% | Miss | N/A | N/A | N/A | May 13, 2021 | $47.54M |
| Dec 31, 2020 | -$0.02 | -$0.02 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 18, 2021 | $37.88M |
| Sep 30, 2020 | -$135.60 | N/A | N/A | N/A | N/A | -362.2% | N/A | N/A | Nov 16, 2020 | $34.56M |
| Sep 30, 2019 | $51.72 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2019 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.04, down 55.6% from the year before. It was -$83.90 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.04 | -55.6% |
| Dec 31, 2024 | $0.09 | -47.1% |
| Dec 31, 2023 | $0.17 | +240.0% |
| Dec 31, 2022 | $0.05 | N/A |
| Dec 31, 2021 | $0.06 | N/A |
| Dec 31, 2020 | -$83.90 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,400 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,386 | 10 | |
| 2026Q2 | Jun 30, 2026 | 5,279 | 11 | |
| 2026Q1 | Mar 31, 2026 | 5,377 | 11 | |
| 2025Q4 | Dec 31, 2025 | 5,817 | 8 | |
| 2025Q3 | Sep 30, 2025 | 5,025 | 10 | |
| 2025Q2 | Jun 30, 2025 | 5,454 | 12 | |
| 2025Q1 | Mar 31, 2025 | 5,043 | 10 | |
| 2024Q4 | Dec 31, 2024 | 6,604 | 11 |
2026Q3 Earnings Call
Opening remarks
Norberto Aja Investor Relations Thank you, operator, and good afternoon, everyone. Thank you for joining SkinHealth Systems' third quarter 2026 conference call. We released our results earlier this afternoon, which can be found on our corporate website at skinhealthsystems.com. Joining me on the call today is SkinHealth Systems President and Chief Executive Officer, Pedro Malha, along with our Chief Financial Officer, Mike Monahan. Before we begin, I want to remind everyone of the company's safe harbor language. Management may make forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including guidance and underlying assumptions. Forward-looking statements are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially. Listeners are cautioned not to place undue reliance on any forward-looking statements. For a further discussion of risks related to our business, please refer to the risk factors contained in the company's filings with the Securities and Exchange Commission. In addition, this call will present non-GAAP financial measures. Management uses adjusted EBITDA and other non-GAAP measures as supplemental measures to evaluate operating performance and to facilitate period-to-period comparisons. These non-GAAP measures should be considered in addition to, and not as a substitute for, financial information prepared in accordance with GAAP. A reconciliation of these non-GAAP financial measures to the most comparable GAAP measure is available in the earnings press release, which was furnished to the SEC, as well as available on our website. Following management's prepared remarks, we will open the call for a question-and-answer session. With that, I would now like to turn the call over to our President and CEO, Pedro Malha. Please go ahead, Pedro.
Pedro Malha President and CEO Thank you, Norberto, and good afternoon, everybody. Let me start with a central message from this quarter. We are making progress on the things that matter the most: stabilizing the Hydrafacial business and improving the economics of the company. At the same time, we are developing new opportunities for growth. To be clear, the work isn't done. Equipment sales remain challenging, particularly in EMEA, and utilization in our installed base is still below where it should be. But we are making good progress against our plan, and the third quarter results provide tangible evidence that we are operating from a stronger foundation than a year ago. Our third quarter revenue was $69.2 million, toward the upper end of our $65 million-$70 million guidance range, meaning that our quarterly revenue declined 2.1% year-over-year, which is a meaningful improvement from the declines of 7.8% in the second quarter and 6.7% in the first quarter.
Frequently Asked Questions About SKIN
When is SkinHealth Systems's next earnings date?
SkinHealth Systems's next earnings report is expected for Mar 10, 2027.
Did SKIN beat earnings estimates last quarter?
Yes. SkinHealth Systems reported EPS of -$0.14 for the quarter ended Sep 30, 2026, above the -$1.32 estimate, a 89.39% surprise.
What EPS do analysts expect from SKIN next quarter?
The consensus EPS estimate for SkinHealth Systems for the quarter ending Dec 31, 2026 is -$0.47 from 11 analysts, with estimates from -$0.96 to -$0.14.
How often does SKIN beat earnings estimates?
SkinHealth Systems beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +120.98%.
SKIN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors